Lv1
50 积分 2025-12-12 加入
Trends in clinical development for PD-1/PD-L1 inhibitors
5天前
已完结
The risk of treatment‐related toxicities with PD‐1/PD‐L1 inhibitors in patients with lung cancer
10天前
已完结
Safety of immune checkpoint inhibitors: A systematic review of disproportionality analysis studies
10天前
已完结
Biliary disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database
10天前
已完结
Early versus late onset hematologic immune-related adverse events following immune checkpoint inhibition: Temporal patterns, clinical profiles, and risk stratification in faers reports (2014–2025)
10天前
已关闭
Bridging FDA Adverse Event Reporting System ( FAERS ) and Clinical Practice: Comprehensive Characterization of Immune Checkpoint Inhibitors Toxicities in Geriatric Lung Cancer Patients
1个月前
已完结
Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014–2022)
2个月前
已完结
Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014–2022)
2个月前
已完结
Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system
3个月前
已完结
Utilizing temporal pattern of adverse event reports to identify potential late-onset adverse events
3个月前
已完结
皖公网安备34019202002308
